From what has been discussed above, current studies on tumor immunotherapy have mainly focused on T-cell immunity, and inhibitory factors exist in every link of the cancer-immunity cycle, which seems to explain the poor efficacy of ICIs for EGFR-mutant NSCLC patients. Here, EGFR is linked to neoplasm.